Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma

Abstract Background Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real‐world data on this regimen are limited in this setting. Methods This retrospective observational study utilized data from the US Oncology Network iKnowMed electroni...

Full description

Saved in:
Bibliographic Details
Main Authors: Wolfram Samlowski, Nicholas J. Robert, Liwei Chen, Brad Schenkel, Catherine Davis, Andriy Moshyk, Srividya Kotapati, Tayla Poretta, Jeffrey S. Weber
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
adjuvant therapy
dosing interval
flat dosing
melanoma
nivolumab
real‐world
Online Access:https://doi.org/10.1002/cam4.5061
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.5061

Similar Items